Skip to content

Lidocaine Combined With Sufentanil for Preventing Catheter-related Bladder Discomfort

Lidocaine Combined With Sufentanil for Preventing Catheter-related Bladder Discomfort After Robot-assisted Radical Prostatectomy: a Randomized, Double-blind, Controlled Trial

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05957653
Enrollment
140
Registered
2023-07-24
Start date
2023-10-07
Completion date
2025-10-30
Last updated
2023-07-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Cancer

Brief summary

The goal of this clinical trial is to evaluate the incidence and severity of postoperative catheter-related bladder discomfort after robot-assisted radical prostatectomy. The main question it aims to answer is to evaluate incidence of CRBD immediately after extubation in resuscitation. A total of 20ml of 2% lidocaine and 1μg/ml sufentanil or 20ml normal saline was injected into the bladder of the participants through the catheter. After drug injection, the catheter was clamped for 20 minutes, and then 100ml normal saline was injected into the bladder through the catheter to flush out. Then, the incidence of CRBD was compared between the two groups.

Interventions

DRUGlidocaine and sufentanil

A total of 20ml of 2% lidocaine and 1μg/ml sufentanil was injected into the bladder through the catheter.

DRUGSaline

A total of 20ml normal saline was injected into the bladder through the catheter.

Sponsors

RenJi Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
MALE
Age
18 Years to 79 Years
Healthy volunteers
No

Inclusion criteria

1. aged 18-79 years, ASA class I-II 2. participants undergoing robot-assisted radical prostatectomy under general anesthesia 3. signed informed consent and volunteered to participate in the experiment

Exclusion criteria

1. urethral stricture, difficulty in inserting catheter or urethral bleeding during catheterization 2. a preexisting bladder disease such as an overactive bladder, bladder outflow obstruction, and neurogenic bladder 3. cognitive impairment or communication disorders 4. severe heart, lung, liver, kidney and immune system diseases 5. confirmed or suspected allergy to this trial drug

Design outcomes

Primary

MeasureTime frameDescription
incidence of CRBDimmediately after extubation in resuscitationincidence of CRBD

Contacts

Primary ContactHao Zhu
zhuhaossmu@163.com008602168383702

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026